Publications for Philip Barter
Publications for Philip Barter
2016
Puranik, R., Bao, B., Bonin, A., Kaur, R., Weder,
J., Casbolt, L., Hambley, T., Lay, P., Barter, P.,
Rye, K. (2016). A novel class of copper(II)- and
zinc(II)-bound non-steroidal anti-inflammatory
drugs that inhibits acute inflammation in vivo.
Cell & Bioscience, 6(1), 1-7. <a
href="http://dx.doi.org/10.1186/s13578-016-007
6-8">[More Information]</a>
Cochran, B., Ryder, W., Parmar, A., Tang, S.,
Reilhac, A., Arthur, A., Charil, A., Hamze, H.,
Barter, P., Kritharides, L., Meikle, S., Gregoire,
M., Rye, K. (2016). In vivo PET imaging with
[18F]FDG to explain improved glucose uptake in
an apolipoprotein A-I treated mouse model of
diabetes. Diabetologia, Article online 18 May
2016. <a
href="http://dx.doi.org/10.1007/s00125-016-399
3-5">[More Information]</a>
2015
Bisoendial, R., Tabet, F., Tak, P., Petrides, F.,
Torres, L., Hou, L., Cook, A., Barter, P.,
Weninger, W., Rye, K. (2015). Apolipoprotein
A-I Limits the Negative Effect of Tumor
Necrosis Factor on Lymphangiogenesis.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 35(11), 2443-2450. <a
href="http://dx.doi.org/10.1161/ATVBAHA.115.
305777">[More Information]</a>
Wu, B., Shrestha, S., Ong, K., Johns, D., Hou,
L., Barter, P., Rye, K. (2015). Cholesteryl ester
transfer protein inhibition enhances endothelial
repair and improves endothelial function in the
rabbit. Arteriosclerosis, Thrombosis, and
Vascular Biology, 35(3), 628-636. <a
href="http://dx.doi.org/10.1161/ATVBAHA.114.
304747">[More Information]</a>
Wu, B., Shrestha, S., Ong, K., Johns, D., Dunn,
L., Hou, L., Barter, P., Rye, K. (2015).
Increasing HDL levels by inhibiting cholesteryl
ester transfer protein activity in rabbits with
hindlimb ischemia is associated with increased
angiogenesis. International Journal of
Cardiology, 199, 204-212. <a
href="http://dx.doi.org/10.1016/j.ijcard.2015.07.
014">[More Information]</a>
Ong, K., Januszewski, A., O'Connell, R., Buizen,
L., Jenkins, A., Xu, A., Sullivan, D., Barter, P.,
Scott, R., Taskinen, M., Rye, K., Keech, A.
(2015). Relationship of fibroblast growth factor
21 with baseline and new on-study microvascular
disease in the Fenofibrate Intervention and Event
Lowering in Diabetes study. Diabetologia, 59(8),
2035-2044. <a
href="http://dx.doi.org/10.1007/s00125-015-365
2-2">[More Information]</a>
Ong, K., Ding, J., McClelland, R., Cheung, B.,
Criqui, M., Barter, P., Rye, K., Allison, M.
(2015). Relationship of pericardial fat with
biomarkers of inflammation and hemostasis, and
cardiovascular disease: The Multi-Ethnic Study
of Atherosclerosis. Atherosclerosis, 239(2),
386-392. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2015.01.033">[More Information]</a>
Ong, K., Ding, J., McClelland, R., Cheung, B.,
Criqui, M., Barter, P., Rye, K., Allison, M.
(2015). Relationship of pericardial fat with
lipoprotein distribution: The Multi-Ethnic study
of atherosclerosis. Atherosclerosis, 241(2),
664-670. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2015.06.027">[More Information]</a>
Ong, K., Januszewski, A., O'Connell, R.,
Jenkins, A., Xu, A., Sullivan, D., Barter, P.,
Hung, W., Scott, R., Taskinen, M., Keech, A.,
Rye, K. (2015). The relationship of fibroblast
growth factor 21 with cardiovascular outcome
events in the Fenofibrate Intervention and Event
Lowering in Diabetes study. Diabetologia, 58(3),
464-473. <a
href="http://dx.doi.org/10.1007/s00125-014-345
8-7">[More Information]</a>
2014
Cochrane, B., Bisoendial, R., Hou, L., Glaros, E.,
Rossy, J., Thomas, S., Barter, P., Rye, K. (2014).
Apolipoprotein a-I increases Insulin Secretion
and Production from Pancreatic β-cells via a
G-protein-cAMP-PKA-FoxO1- Dependent
Mechanism. Arteriosclerosis, Thrombosis, and
Vascular Biology, 34(10), 2261-2267. <a
href="http://dx.doi.org/10.1161/ATVBAHA.114.
304131">[More Information]</a>
Ong, K., Barter, P., Waters, D. (2014).
Cardiovascular drugs that increase the risk of
new-onset diabetes. American Heart Journal,
167(4), 421-428. <a
href="http://dx.doi.org/10.1016/j.ahj.2013.12.02
5">[More Information]</a>
Ong, K., Waters, D., Messig, M., DeMicco, D.,
Rye, K., Barter, P. (2014). Effect of Change in
Body Weight on Incident Diabetes Mellitus in
Patients With Stable Coronary Artery Disease
Treated With Atorvastatin (from the Treating to
New Targets Study). The American Journal of
Cardiology, 113(10), 1593-1598. <a
href="http://dx.doi.org/10.1016/j.amjcard.2014.0
2.011">[More Information]</a>
Tabet, F., Vickers, K., Cuesta Torres, L., Wiese,
C., Shoucri, B., Lambert, G., Catherinet, C.,
Prado-Lourenco, L., Levin, M., Thacker, S.,
Barter, P., Rye, K., et al (2014). HDL-transferred
microRNA-223 regulates ICAM-1 expression in
endothelial cells. Nature Communications, 5,
Publications for Philip Barter
1-14. <a
href="http://dx.doi.org/10.1038/ncomms4292">[
More Information]</a>
McGrath, K., Li, X., Whitworth, P., Kasz, R.,
Tan, J., McLennan, S., Celermajer, D., Barter, P.,
Rye, K., Heather, A. (2014). High density
lipoproteins improve insulin sensitivity in
high-fat diet-fed mice by suppressing hepatic
inflammation. Journal of Lipid Research
(Online), 55(3), 421-430. <a
href="http://dx.doi.org/10.1194/jlr.M043281">[
More Information]</a>
Wu, B., Ong, K., Shrestha, S., Chen, K., Tabet,
F., Barter, P., Rye, K. (2014). Inhibition of
Arthritis in the Lewis Rat by Apolipoprotein A-I
and Reconstituted High-Density Lipoproteins.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 34(3), 543-551. <a
href="http://dx.doi.org/10.1161/ATVBAHA.113.
302832">[More Information]</a>
Ong, K., McClelland, R., Rye, K., Cheung, B.,
Post, W., Vaidya, D., Criqui, M., Cushman, M.,
Barter, P., Allison, M. (2014). The relationship
between insulin resistance and vascular
calcification in coronary arteries, and the
thoracic and abdominal aorta: The Multi-Ethnic
Study of Atherosclerosis. Atherosclerosis,
236(2), 257-262. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2014.07.01">[More Information]</a>
Ong, K., Allison, M., Cheung, B., Wu, B.,
Barter, P., Rye, K. (2014). The Relationship
between Total Bilirubin Levels and
Total Mortality in Older Adults: The United
States
National Health and Nutrition Examination
Survey
(NHANES) 1999-2004. PloS One, 9(14), 1-8. <a
href="http://dx.doi.org/10.1371/journal.pone.009
4479">[More Information]</a>
2013
Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K.
(2013). Arthritis: Its prevalence, risk factors, and
association with cardiovascular diseases in the
United States, 1999 to 2008. Annals of
Epidemiology, 23(2), 80-86. <a
href="http://dx.doi.org/10.1016/j.annepidem.201
2.11.008">[More Information]</a>
Wu, B., Chen, K., Shrestha, S., Ong, K., Barter,
P., Rye, K. (2013). High Density Lipoproteins
Inhibit Vascular Endothelial Inflammation by
Increasing 3[beta]-Hydroxysteroid-Delta24
Reductase Expression and Inducing Heme
Oxygenase-1. Circulation Research, 112(2),
278-288. <a
href="http://dx.doi.org/10.1161/CIRCRESAHA.
111.300104">[More Information]</a>
Ong, K., Allison, M., Cheung, B., Wu, B.,
Barter, P., Rye, K. (2013). Trends in C-Reactive
Protein Levels in US Adults From 1999 to 2010.
American Journal of Epidemiology, 177(12),
1430-1442. <a
href="http://dx.doi.org/10.1093/aje/kws443">[M
ore Information]</a>
2012
Nicholls, S., Gordon, A., Johannson, J.,
Ballantyne, C., Barter, P., Brewer, H., Kastelein,
J., Wong, N., Borgman, M., Nissen, S. (2012).
ApoA-I Induction as a Potential Cardioprotective
Strategy: Rationale for the SUSTAIN and
ASSURE Studies. Cardiovascular Drugs and
Therapy, 26(2), 181-187. <a
href="http://dx.doi.org/10.1007/s10557-012-637
3-1">[More Information]</a>
Morales-Villegas, E., Moreno-Virgen, G., Barter,
P. (2012). CETP pharmacological manipulation
transforming human into mouse: Is this still a
viable hypothesis? Immunology, Endocrine and
Metabolic Agents in Medicinal Chemistry, 12(4),
266-278. <a
href="http://dx.doi.org/10.2174/1871522128035
21057">[More Information]</a>
Barter, P., Rye, K. (2012). Cholesteryl ester
transfer protein inhibition as a strategy to reduce
cardiovascular risk. Journal of Lipid Research,
53(9), 1755-1766. <a
href="http://dx.doi.org/10.1194/jlr.R024075">[
More Information]</a>
Ong, K., Rye, K., O'Connell, R., Jenkins, A.,
Brown, C., Xu, A., Sullivan, D., Barter, P.,
Keech, A. (2012). Long-Term Fenofibrate
Therapy Increases Fibroblast Growth Factor 21
and Retinol-Binding Protein 4 in Subjects with
Type 2 Diabetes. Journal of Clinical
Endocrinology and Metabolism, 97(12),
4701-4708. <a
href="http://dx.doi.org/10.1210/jc.2012-2267">[
More Information]</a>
Wu, B., Chen, K., Barter, P., Rye, K. (2012).
Niacin Inhibits Vascular Inflammation via the
Induction of Heme Oxygenase-1. Circulation,
125(1), 150-158. <a
href="http://dx.doi.org/10.1161/CIRCULATION
AHA.111.053108">[More Information]</a>
Tso, C., Rye, K., Barter, P. (2012). Phenotypic
and functional changes in blood monocytes
following adherence to endothelium. PloS One,
7(5), 1-11. <a
href="http://dx.doi.org/10.1371/journal.pone.003
7091">[More Information]</a>
Huijgen, R., Boekholdt, S., Arsenault, B., Bao,
W., Davaine, J., Tabet, F., Petrides, F., Rye, K.,
DeMicco, D., Barter, P., et al (2012). Plasma
Publications for Philip Barter
PCSK9 Levels and Clinical Outcomes in the
TNT (Treating to New Targets) Trial: A Nested
Case-Control Study. Journal of the American
College of Cardiology, 59(20), 1778-1784. <a
href="http://dx.doi.org/10.1016/j.jacc.2011.12.04
3">[More Information]</a>
Rye, K., Barter, P. (2012). Predictive value of
different HDL particles for the protection against
or risk of coronary heart disease. Biochimica et
Biophysica Acta. Molecular and Cell Biology of
Lipids, 1821 (3), 473-480. <a
href="http://dx.doi.org/10.1016/j.bbalip.2011.10.
012">[More Information]</a>
Barter, P., Rye, K., Beltangady, M., Ports, W.,
Duggan, W., Boekholdt, S., DeMicco, D.,
Kastelein, J., Shear, C. (2012). Relationship
between atorvastatin dose and the harm caused
by torcetrapib. Journal of Lipid Research,
53(11), 2436-2442. <a
href="http://dx.doi.org/10.1194/jlr.P026328">[M
ore Information]</a>
Arsenault, B., Boekholdt, S., Hovingh, G., Hyde,
C., DeMicco, D., Chatterjee, A., Barter, P.,
Deedwania, P., Waters, D., LaRosa, J., et al
(2012). The 719Arg Variant of KIF6 and
Cardiovascular Outcomes in Statin-Treated,
Stable Coronary Patients of the Treating to New
Targets and Incremental Decrease in End Points
Through Aggressive Lipid-Lowering Prospective
Studies. Circulation Cardiovascular Genetics,
5(1), 51-57. <a
href="http://dx.doi.org/10.1161/CIRCGENETIC
S.111.960252">[More Information]</a>
Drew, B., Rye, K., Duffy, S., Barter, P.,
Kingwell, B. (2012). The emerging role of HDL
in glucose metabolism. Nature Reviews
Endocrinology, 8(4), 237-245. <a
href="http://dx.doi.org/10.1038/nrendo.2011.235
">[More Information]</a>
Rye, K., Barter, P. (2012). The inhibition of
cholesteryl ester transfer protein: a long and
winding road. Journal of Lipid Research, 53(6),
1039-1041. <a
href="http://dx.doi.org/10.1194/jlr.E027334">[M
ore Information]</a>
<a
href="http://dx.doi.org/10.1016/j.tips.2011.07.00
4">[More Information]</a>
Chan, J., Chan, S., Deerochanawong, C., Go, R.,
Lee, K., Ma, R., Pan, C., Sheu, W., Barter, P.
(2011). Diabetic dyslipidaemia in Asian
populations in the Western Pacific Region: What
we know and don't know. Diabetes Research and
Clinical Practice, 94(1), 1-13. <a
href="http://dx.doi.org/10.1016/j.diabres.2011.05
.034">[More Information]</a>
Barter, P., Rye, K., Tardif, J., Waters, D.,
Boekholdt, S., Breazna, A., Kastelein, J. (2011).
Effect of Torcetrapib on Glucose, Insulin, and
Hemoglobin A1c in Subjects in the Investigation
of Lipid Level Management to Understand its
Impact in Atherosclerotic Events
(ILLUMINATE) Trial. Circulation, 124(5),
555-562. <a
href="http://dx.doi.org/10.1161/CIRCULATION
AHA.111.018259">[More Information]</a>
Nicholls, S., Ballantyne, C., Barter, P., Chapman,
M., Erbel, R., Libby, P., Raichlen, J., Uno, K.,
Borgman, M., Wolski, K., et al (2011). Effect of
Two Intensive Statin Regimens on Progression
of Coronary Disease. New England Journal of
Medicine, 365(22), 2078-2087. <a
href="http://dx.doi.org/10.1056/NEJMoa111087
4">[More Information]</a>
Watts, G., Sullivan, D., Poplawski, N., van
Bockxmeer, F., Hamilton-Craig, I., Clifton, P.,
O'Brien, R., Bishop, W., George, P., Barter, P.,
Freeman, L., Krass, I., Trent, R., et al (2011).
Familial hypercholesterolaemia: A model of care
for Australasia. Atherosclerosis Supplements, 12,
221-263. <a
href="http://dx.doi.org/10.1016/j.atherosclerosiss
up.2011.06.001">[More Information]</a>
Barter, P. (2011). HDL-C: Role as a risk
modifier. Atherosclerosis Supplements, 12(3),
267-270. <a
href="http://dx.doi.org/10.1016/S1567-5688(11)
70885-6">[More Information]</a>
Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K.
(2011). Association of lower total bilirubin level
with statin usage: The United States National
Health and Nutrition Examination Survey
1999-2008. Atherosclerosis, 219(2), 728-733. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2011.07.094">[More Information]</a>
Nicholls, S., Borgman, M., Nissen, S., Raichlen,
J., Ballantyne, C., Barter, P., Chapman, M.,
Erbel, R., Libby, P. (2011). Impact of statins on
progression of atherosclerosis: rationale and
design of SATURN (Study of Coronary
Atheroma by InTravascular Ultrasound: Effect of
Rosuvastatin versus AtorvastatiN). Current
Medical Research and Opinion, 27(6),
1119-1129. <a
href="http://dx.doi.org/10.1185/03007995.2011.
570746">[More Information]</a>
Barter, P., Rye, K. (2011). Cholesteryl ester
transfer protein inhibition to reduce
cardiovascular risk: where are we now? Trends
In Pharmacological Sciences, 32(12), 694-699.
Reimers, G., Jackson, C., Rickards, J., Chan, P.,
Cohn, J., Rye, K., Barter, P., Rodgers, K. (2011).
Inhibition of rupture of established
atherosclerotic plaques by treatment with
2011
Publications for Philip Barter
apolipoprotein A-I. Cardiovascular Research,
91(1), 37-44. <a
href="http://dx.doi.org/10.1093/cvr/cvr057">[M
ore Information]</a>
Tabet, F., Lambert, G., Torres, L., Hou, L.,
Sotirchos, I., Touyz, R., Jenkins, A., Barter, P.,
Rye, K. (2011). Lipid-Free Apolipoprotein A-I
and Discoidal Reconstituted High-Density
Lipoproteins Differentially Inhibit
Glucose-Induced Oxidative Stress in Human
Macrophages. Arteriosclerosis, Thrombosis, and
Vascular Biology, 31(5), 1192-1200. <a
href="http://dx.doi.org/10.1161/ATVBAHA.110.
222000">[More Information]</a>
Arsenault, B., Barter, P., DeMicco, D., Bao, W.,
Preston, G., LaRosa, J., Grundy, S., Deedwania,
P., Greten, H., Wenger, N., et al (2011).
Prediction of cardiovascular events in
statin-treated stable coronary patients by lipid
and nonlipid biomarkers. Journal of the
American College of Cardiology, 57(1), 63-69.
<a
href="http://dx.doi.org/10.1016/j.jacc.2010.06.05
2">[More Information]</a>
Waters, D., Ho, J., DeMicco, D., Breazna, A.,
Arsenault, B., Wun, C., Kastelein, J., Colhoun,
H., Barter, P. (2011). Predictors of new-onset
diabetes in patients treated with atorvastatin:
results from 3 large randomized clinical trials.
Journal of the American College of Cardiology,
57(14), 1535-1545. <a
href="http://dx.doi.org/10.1016/j.jacc.2010.10.04
7">[More Information]</a>
Barter, P. (2011). Raising HDL-C can be
achieved by both lifestyle changes and
pharmacological means. Introduction.
Atherosclerosis Supplements, 12(3), 265-266. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=22272435">[More Information]</a>
Ong, K., Barter, P., Rye, K. (2011). Response to
statin use and serum bilirubin levels.
Atherosclerosis, 219(2), 392-392.
Preiss, D., Seshasai, S., Welsh, P., Murphy, S.,
Ho, J., Waters, D., DeMicco, D., Barter, P.,
Sabatine, M., Cannon, C., et al (2011). Risk of
incident diabetes with intensive-dose compared
with moderate-dose statin therapy: a
meta-analysis. JAMA, 305(24), 2556-2564. <a
href="http://dx.doi.org/10.1001/jama.2011.860">
[More Information]</a>
Di Bartolo, B., Nicholls, S., Bao, B., Rye, K.,
Heather, A., Barter, P., Bursill, C. (2011). The
apolipoprotein A-I mimetic peptide ETC-642
exhibits anti-inflammatory properties that are
comparable to high density lipoproteins.
Atherosclerosis, 217(2), 395-400. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2011.04.001">[More Information]</a>
Di Bartolo, B., Vanags, L., Tan, J., Bao, B., Rye,
K., Barter, P., Bursill, C. (2011). The
apolipoprotein A-I mimetic peptide, ETC-642,
reduces chronic vascular inflammation in the
rabbit. Lipids in Health and Disease,
10(NOvember), A224-1-A224-8. <a
href="http://dx.doi.org/10.1186/1476-511X-10-2
24">[More Information]</a>
Barter, P. (2011). The causes and consequences
of low levels of high density lipoproteins in
patients with diabetes. Journal of Diabetes &
Metabolism, 35(2), 101-106. <a
href="http://dx.doi.org/10.4093/dmj.2011.35.2.1
01">[More Information]</a>
2010
Taskinen, M., Barter, P., Ehnholm, C., Sullivan,
D., Mann, K., Simes, R., Best, J., Hamwood, S.,
Keech, A. (2010). Ability of traditional lipid
ratios and apolipoprotein ratios to predict
cardiovascular risk in people with type 2
diabetes. Diabetologia, 53(9), 1846-1855. <a
href="http://dx.doi.org/10.1007/s00125-010-180
6-9">[More Information]</a>
Patel, S., Di Bartolo, B., Nakhla, S., Heather, A.,
Mitchell, T., Jessup, W., Celermajer, D., Barter,
P., Rye, K. (2010). Anti-inflammatory effects of
apolipoprotein A-I in the rabbit. Atherosclerosis,
212(2), 392-397. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2010.05.035">[More Information]</a>
Barter, P., Brandrup-Wognsen, G., Palmer, M.,
Nicholls, S. (2010). Effect of statins on HDL-C:
a complex process unrelated to changes in
LDL-C: analysis of the VOYAGER Database.
Journal of Lipid Research, 51(6), 1546-1553. <a
href="http://dx.doi.org/10.1194/jlr.P002816">[M
ore Information]</a>
Fryirs, M., Barter, P., Appavoo, M., Tuch, B.,
Tabet, F., Heather, A., Rye, K. (2010). Effects of
High-Density Lipoproteins on Pancreatic
beta-Cell Insulin Secretion. Arteriosclerosis,
Thrombosis, and Vascular Biology, 30(8),
1642-1648. <a
href="http://dx.doi.org/10.1161/ATVBAHA.110.
207373">[More Information]</a>
Wu, B., Yan, L., Charlton, F., Witting, P., Barter,
P., Rye, K. (2010). Evidence that niacin inhibits
acute vascular inflammation and improves
endothelial dysfunction independent of changes
in plasma lipids. Arteriosclerosis, Thrombosis,
and Vascular Biology, 30(5), 968-975. <a
href="http://dx.doi.org/10.1161/ATVBAHA.109.
201129">[More Information]</a>
Laurila, P., Naukkarinen, J., Ripatti, S., Kauttu,
T., Silander, K., Salomaa, V., Perola, M.,
Karhunen, P., Barter, P., Ehnholm, C., et al
Publications for Philip Barter
(2010). Genetic Association and Interaction
Analysis of USF1 and APOA5 on Lipid Levels
and Atherosclerosis. Arteriosclerosis,
Thrombosis, and Vascular Biology, 30(2),
346-352. <a
href="http://dx.doi.org/10.1161/ATVBAHA.109.
188912">[More Information]</a>
Waterworth, D., Ricketts, S., Song, K., Chen, L.,
Zhao, J., Ripatti, S., Aulchenko, Y., Zhang, W.,
Yuan, X., Lim, N., et al (2010). Genetic variants
influencing circulating lipid levels and risk of
coronary artery disease. Arteriosclerosis,
Thrombosis, and Vascular Biology, 30(11),
2264-2276. <a
href="http://dx.doi.org/10.1161/ATVBAHA.109.
201020">[More Information]</a>
Bursill, C., Castro, M., Beattie, D., Nakhla, S.,
van der Vorst, E., Heather, A., Barter, P., Rye, K.
(2010). High-Density Lipoproteins Suppress
Chemokines and Chemokine Receptors In Vitro
and In Vivo. Arteriosclerosis, Thrombosis, and
Vascular Biology, 30(9), 1773-1778. <a
href="http://dx.doi.org/10.1161/ATVBAHA.110.
211342">[More Information]</a>
Nicholls, S., Brandrup-Wognsen, G., Palmer, M.,
Barter, P. (2010). Meta-analysis of comparative
efficacy of increasing dose of Atorvastatin versus
Rosuvastatin versus Simvastatin on lowering
levels of atherogenic lipids (from VOYAGER).
The American Journal of Cardiology, 105(1),
69-76. <a
href="http://dx.doi.org/10.1016/j.amjcard.2009.0
8.651">[More Information]</a>
Nobecourt, E., Tabet, F., Lambert, G., Puranik,
R., Bao, B., Yan, L., Davies, M., Brown, B.,
Jenkins, A., Dusting, G., Barter, P., Rye, K., et al
(2010). Nonenzymatic Glycation Impairs the
Antiinflammatory Properties of Apolipoprotein
A-I. Arteriosclerosis, Thrombosis, and Vascular
Biology, 30(4), 766-772. <a
href="http://dx.doi.org/10.1161/ATVBAHA.109.
201715">[More Information]</a>
Cannon, C., Shah, S., Dansky, H., Davidson, M.,
Brinton, E., Gotto Jnr, A., Stepanavage, M., Liu,
S., Gibbons, P., Ashraf, T., Barter, P., et al
(2010). Safety of Anacetrapib in Patients with or
at High Risk for Coronary Heart Disease. New
England Journal of Medicine, 363(25),
2406-2415. <a
href="http://dx.doi.org/10.1056/NEJMoa100974
4">[More Information]</a>
Tabet, F., Remaley, A., Segaliny, A., Millet, J.,
Yan, L., Nakhla, S., Barter, P., Rye, K., Lambert,
G. (2010). The 5A Apolipoprotein A-I Mimetic
Peptide Displays Antiinflammatory and
Antioxidant Properties In Vivo and In Vitro.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 30(2), 246-252. <a
href="http://dx.doi.org/10.1161/ATVBAHA.109.
200196">[More Information]</a>
Barter, P. (2010). The Relationship between
Cholesteryl Ester Transfer Protein and
Cardiovascular Risk. Clinical Chemistry, 56(10),
1547-9. <a
href="http://dx.doi.org/10.1373/clinchem.2010.1
50565">[More Information]</a>
2009
Patel, S., Puranik, R., Nakhla, S., Lundmand, P.,
Stocker, R., Wang, X., Lambert, G., Rye, K.,
Barter, P., Nicholls, S., Celermajer, D. (2009).
Acute hypertriglyceridaemia in humans increases
the triglyceride content and decreases the
anti-inflammatory capacity of high density
lipoproteins. Atherosclerosis, 204(2), 424-428.
<a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2008.07.047">[More Information]</a>
Fryirs, M., Barter, P., Rye, K. (2009).
Cholesterol metabolism and pancreatic B-cell
function. Current Opinion in Lipidology, 20(3),
159-164. <a
href="http://dx.doi.org/10.1097/MOL.0b013e328
32ac180">[More Information]</a>
Barter, P. (2009). Evolving Targets of Therapy.
In Christie M Ballantyne (Eds.), Clinical
Lipidology: A Companion to Braunwalds Heart
Disease, (pp. 387-395). Philadelphia, USA:
Saunders Elsevier.
Ling, H., Waterworth, D., Stirnadel, H., Pollin,
T., Barter, P., Kesaniemi, Y., Mahley, R.,
McPherson, R., Waeber, G., Bersot, T., et al
(2009). Genome-wide linkage and association
analyses to identify genes influencing
adiponectin levels: the GEMS Study. Obesity,
17(4), 737-744. <a
href="http://dx.doi.org/10.1038/oby.2008.625">[
More Information]</a>
Barter, P., Rye, K. (2009). High-density
lipoprotein as a therapeutic target. In Tonkin,
Andrew (Eds.), Therepeutic Strategies: Lipid
Disorders, (pp. 29-42). United Kingdom:
Clinical Publishing, Oxford.
Barter, P. (2009). Lessons learned from the
Investigation of Lipid Level Management to
Understand its Impact in Atherosclerotic Events
(ILLUMINATE) trial. The American Journal of
Cardiology, 104(10 Suppl), 10E-15E. <a
href="http://dx.doi.org/10.1016/j.amjcard.2009.0
9.014">[More Information]</a>
Chirovsky, D., Fedirko, V., Cui, Y., Sazonov, V.,
Barter, P. (2009). Prospective studies on the
relationship between high-density lipoprotein
cholesterol and cardiovascular risk: a systematic
review. European Journal of Cardiovascular
Prevention and Rehabilitation, 16(4), 404-423.
Publications for Philip Barter
<a
href="http://dx.doi.org/10.1097/HJR.0b013e328
32c8891">[More Information]</a>
Patel, S., Drew, B., Nakhla, S., Duffy, S.,
Murphy, A., Barter, P., Rye, K., Chin-Dusting,
J., Hoang, A., Sviridov, D., Celermajer, D., et al
(2009). Reconstituted high-density lipoprotein
increases plasma high-density lipoprotein
anti-inflammatory properties and cholesterol
efflux capacity in patients with type 2 diabetes.
Journal of the American College of Cardiology,
53(11), 962-971. <a
href="http://dx.doi.org/10.1016/j.jacc.2008.12.00
8">[More Information]</a>
Tabet, F., Barter, P., Rye, K. (2008).
Apolipoprotein A-I and Reconstituted
High-Density Lipoproteins Inhibit NADPH
Oxidase Activation and Expression and Increase
Superoxide Dismutase Levels in Human
Macrophages in High Glucose Conditions.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 28(6), e-87.
Barter, P., Ginsberg, H. (2008). Effectiveness of
Combined Statin Plus Omega-3 Fatty Acid
Therapy for Mixed Dyslipidemia. The American
Journal of Cardiology, 102(8), 1040-1045. <a
href="http://dx.doi.org/10.1016/j.amjcard.2008.0
5.056">[More Information]</a>
Peshavariya, H., Dusting, G., Di Bartolo, B.,
Rye, K., Barter, P., Jiang, F. (2009).
Reconstituted high-density lipoprotein
suppresses leukocyte NADPH oxidase activation
by disrupting lipid rafts. Free Radical Research,
43(8), 772-782. <a
href="http://dx.doi.org/10.1080/1071576090304
5304">[More Information]</a>
Nobécourt, E., Zeng, J., Davies, M., Bronwyn,
B., Yadav, S., Barter, P., Rye, K. (2008). Effects
of cross-link breakers, glycation inhibitors and
insulin sensitisers on HDL function and the
non-enzymatic glycation of apolipoprotein A-I.
Diabetologia, 51(6), 1008-1017. <a
href="http://dx.doi.org/10.1007/s00125-008-098
6-z">[More Information]</a>
Taskinen, M., Sullivan, D., Ehnholm, C.,
Whiting, M., Zannino, D., Simes, R., Keech, A.,
Barter, P. (2009). Relationships of HDL
cholesterol, ApoA-I, and ApoA-II with
homocysteine and creatinine in patients with
Type 2 diabetes treated with fenofibrate.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 29(6), 950-955. <a
href="http://dx.doi.org/10.1161/ATVBAHA.108.
178228">[More Information]</a>
Stirnadel, H., Lin, X., Ling, H., Song, K., Barter,
P., Kesaniemi, Y., Mahley, R., McPherson, R.,
Waeber, G., Bersot, T., et al (2008). Genetic and
phenotypic architecture of metabolic
syndrome-associated components in
dyslipidemic and normolipidemic subjects: The
GEMS Study. Atherosclerosis, 197(2), 868-876.
<a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2007.07.038">[More Information]</a>
McGrath, K., Li, X., Puranik, R., Liong, E., Tan,
J., Dy, V., Di Bartolo, B., Barter, P., Rye, K.,
Heather, A. (2009). Role of
3beta-hydroxysteroid-delta 24 reductase in
mediating
Homer, V., Marais, A., Charlton, F., Laurie, A.,
Hurndell, N., Scott, R., Mangili, F., Sullivan, D.,
Barter, P., Rye, K., et al (2008). Identification
and characterization of two non-secreted PCSK9
mutants associated with familial
hypercholesterolemia in cohorts from New
Zealand and South Africa. Atherosclerosis,
196(2), 659-666. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2007.07.022">[More Information]</a>
antiinflammatory effects of high-density
lipoproteins in endothelial
cells. Arteriosclerosis, Thrombosis, and Vascular
Biology, 29(6), 877-882. <a
href="http://dx.doi.org/10.1161/ATVBAHA.109.
184663">[More Information]</a>
Rye, K., Bursill, C., Lambert, G., Tabet, F.,
Barter, P. (2009). The metabolism and
anti-atherogenic properties of HDL. Journal of
Lipid Research, 50(Supplement), S195-S200. <a
href="http://dx.doi.org/10.1194/jlr.R800034-JLR
200">[More Information]</a>
2008
Rye, K., Barter, P. (2008). Antiinflammatory
Actions of HDL. Arteriosclerosis, Thrombosis,
and Vascular Biology, 28(11), 1890-1891. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18946054">[More Information]</a>
Di Bartolo, B., Bao, B., Rye, K., Nicholls, S.,
Barter, P. (2008). In Vivo Properties of a Novel
Apolipoprotein A-1 Mimetic Peptide. Journal of
the American College of Cardiology, 51(10),
A283.
Shah, S., Waters, D., Barter, P., Kastelein, J.,
Shepherd, J., Wenger, N., DeMicco, D., Breazna,
A., LaRosa, J. (2008). Intensive Lipid-Lowering
With Atorvastatin for Secondary Prevention in
Patients After Coronary Artery Bypass Surgery.
Journal of the American College of Cardiology,
51(20), 1938-1943. <a
href="http://dx.doi.org/10.1016/j.jacc.2007.12.05
4">[More Information]</a>
Barter, P., Rye, K. (2008). Is There a Role for
Fibrates in the Management of Dyslipidemia in
Publications for Philip Barter
the Metabolic Syndrome? Arteriosclerosis,
Thrombosis, and Vascular Biology, 28(1), 39-46.
<a
href="http://dx.doi.org/10.1161/ATVBAHA.107.
148817">[More Information]</a>
Sandhu, M., Waterworth, D., Debenham, S.,
Wheeler, E., Papadakis, K., Zhao, J., Song, K.,
Yuan, X., Johnson, T., Ashford, S., Barter, P., et
al (2008). LDL-cholesterol concentrations: a
genome-wide association study. The Lancet,
371(9611), 483-491. <a
href="http://dx.doi.org/10.1016/S0140-6736(08)
60208-1">[More Information]</a>
Kastelein, J., van der Steeg, W., Holme, I.,
Gaffney, M., Cater, N., Barter, P., Deedwania,
P., Olsson, A., Boekholdt, S., DeMicco, D., et al
(2008). Lipids, Apolipoproteins, and Their
Ratios in Relation to Cardiovascular Events With
Statin Treatment. Circulation, 117(23),
3002-3009. <a
href="http://dx.doi.org/10.1161/CIRCULATION
AHA.107.713438">[More Information]</a>
Puranik, R., Bao, B., Nobecourt, E., Nicholls, S.,
Dusting, G., Barter, P., Celermajer, D., Rye, K.
(2008). Low dose apolipoprotein A-I rescues
carotid arteries from inflammation in vivo.
Atherosclerosis, 196(1), 240-247. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2007.05.008">[More Information]</a>
Lambert, G., Ancellin, N., Charlton, F., Comas,
D., Pilot, J., Keech, A., Patel, S., Sullivan, D.,
Cohn, J., Rye, K., Barter, P. (2008). Plasma
PCSK9 Concentrations Correlate with LDL and
Total Cholesterol in Diabetic Patients and Are
Decreased by Fenofibrate Treatment. Clinical
Chemistry, 54(6), 1038-1045. <a
href="http://dx.doi.org/10.1373/clinchem.2007.0
99747">[More Information]</a>
Settasatian, N., Barter, P., Rye, K. (2008).
Remodeling of apolipoprotein E-containing
spherical reconstituted high density lipoproteins
by phospholipid transfer protein. Journal of
Lipid Research, 49(1), 115-126. <a
href="http://dx.doi.org/10.1194/jlr.M700220-JL
R200">[More Information]</a>
2007
Kastelein, J., Barter, P. (2007). A comparison of
the association of on-treatment lipid and
apolipoprotein parameters to cardiovascular
events in ideal and TNT. Atherosclerosis
Supplements, 8, 196.
Patel, S., Drew, B., Duffy, S., Nahkla, S., Rye,
K., Barter, P., Celermajer, D., Kingwell, B.
(2007). Abstract 1047: Infusion of Reconstituted
High Density Lipoproteins Into Humans
Enhances the In Vitro Anti-Inflammatory
Capacity of the High Density Lipoprotein
Fraction. Circulation, 116, II_209.
Scott, R., D'Emden, M., Best, J., Drury, P.,
Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D.,
Barter, P., Taskinen, M., Copt, S., Keech, A., et
al (2007). Abstract 3691: Features Of Metabolic
Syndrome Identify Individuals With Type 2
Diabetes Mellitus At High Risk For
Cardiovascular Events And Greater Absolute
Benefits Of Fenofibrate. Circulation, 116,
II_838.
Barter, P., Shear, C. (2007). Aggressive
Management of Obesity in Children and Young
Adults: The Known Challenges and Potential
Opportunities. Clinical Pharmacology &
Therapeutics, 81(5), 627-630. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17438536">[More Information]</a>
Kastelein, J., van Leuven, S., Burgess, L., Evans,
G., Kuivenhoven, J., Barter, P., Revkin, J.,
Grobbee, D., Riley, W., Shear, C., et al (2007).
Effect of Torcetrapib on Carotid Atherosclerosis
in Familial Hypercholesterolemia. New England
Journal of Medicine, 356, 1620-1630. <a
href="http://dx.doi.org/10.1056/NEJMoa071359
">[More Information]</a>
Barter, P., Caulfield, M., Eriksson, M., Grundy,
S., Kastelein, J., Komajda, M., Lopez-Sendon, J.,
Mosca, L., Tardif, J., Waters, D., et al (2007).
Effects of Torcetrapib in Patients at High Risk
for Coronary Events. New England Journal of
Medicine, 357(21), 2109-2122. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17984165">[More Information]</a>
Barter, P., Rye, K. (2007). HDL and
Atherosclerosis. In Christopher J Fielding
(Eds.), High Density Lipoproteins: From Basic
Biology to Clinical Aspects, (pp. 491-505).
Germany: Wiley - V C H Verlag GmbH & Co.
KGaA.
Barter, P., Gotto, A., laRosa, J., Maroni, J.,
Szarek, M., Grundy, S., Kastelein, J., Bittner, V.,
Fruchart, J. (2007). HDL cholesterol, very low
levels of LDL cholesterol, and cardiovascular
events. New England Journal of Medicine,
357(13), 1301-1310. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17898099">[More Information]</a>
Barter, P., Rye, K. (2007). HDL structure and
metabolism: Its regulation by cell membrane
receptors. In C J Packard (Eds.), The Year in
Lipid Disorders. Volume 1, (pp. 93-112). United
Kingdom: Clinical Publishing, Oxford.
Homer, V., Marais, A., Laurie, A., Charlton, F.,
Sullivan, D., Barter, P., Rye, K., George, P.,
Publications for Philip Barter
Lambert, G. (2007). Identification and Molecular
Characterization of New PCSK9 Missense
Mutations Associated with Familial
Hypercholesterolemia. Arteriosclerosis,
Thrombosis, and Vascular Biology, 27(6), e-122.
Barter, P. (2007). Torcetrapib - Final results of
the ILLUMINATE trial. Circulation, 116(22),
2630.
Balkau, B., Deanfield, J., Despres, J., Bassand,
J., Fox, K., Smith, S., Barter, P., Tan, C., Van
Gaal, L., Wittchen, H., et al (2007). International
Day for the Evaluation of Abdominal Obesity
(IDEA): A Study of Waist Circumference,
Cardiovascular Disease, and Diabetes Mellitus in
168 000 Primary Care Patients in 63 Countries.
Circulation, 116(17), 1942-1951. <a
href="http://dx.doi.org/10.1161/CIRCULATION
AHA.106.676379">[More Information]</a>
Puranik, R., Bao, B., Celermajer, D., Rye, K.,
Barter, P., Nicholls, S., Nobecourt, E. (2006). A
single infusion of lipid free apo A1 can rescue
vascular inflammation. Atherosclerosis
Supplements, 7, 153.
Skropeta, D., Settasatian, C., McMahon, M.,
Shearston, K., Caiazza, D., McGrath, K., Jin, W.,
Rader, D., Barter, P., Rye, K. (2007).
N-Glycosylation regulates endothelial
lipase-mediated phospholipid hydrolysis in
apoE- and apoA-I-containing high density
lipoproteins. Journal of Lipid Research, 48(9),
2047-2057. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17545692">[More Information]</a>
Barter, P., Puranik, R., Rye, K. (2007). New
insights into the role of HDL as an
antiinflammatory agent in the prevention of
cardiovascular disease. Current Cardiology
Reports, 9(6), 493-498. <a
href="http://dx.doi.org/10.1007/BF02938394">[
More Information]</a>
Barter, P., McPherson, Y., Song, K., Kesaeniemi,
Y., Mahley, R., Waeber, G., Bersot, T., Mooser,
V., Waterworth, D., Grundy, S. (2007). Serum
insulin and inflammatory markers in overweight
individuals with and without dyslipidemia.
Journal of Clinical Endocrinology and
Metabolism, 92(6), 2041-2045. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17389699">[More Information]</a>
Barter, P. (2007). Targeting Cholesterol Ester
Transfer Protein for the Prevention and
Management of Cardiovascular Disease.
International Journal of Cardiology, 122(Suppl
1), S9.
Nobecourt, E., Davies, M., Brown, B., Curtiss,
L., Bonnet, D., Charlton, F., Januszewski, A.,
Jenkins, A., Barter, P., Rye, K. (2007). The
impact of glycation on apolipoprotein A-I
structure and its ability to activate
lecithin:cholesterol acyltransferase.
Diabetologia, 50(3), 643-653. <a
href="http://dx.doi.org/10.1007/s00125-006-057
4-z">[More Information]</a>
2006
Puranik, R., Nobecourt, E., Bao, B., Davies, M.,
Barter, P., Celermajer, D., Rye, K. (2006).
Abstract 1355: The Impact of Glycation on the
Anti-inflammatory Properties of High Density
Lipoproteins in vivo. Circulation, 114,
II-257-II-258.
Kastelein, J., Holme, I., Barter, P., Olsson, A.,
Cater, N., DeMicco, D., Gaffney, M., Szarek,
M., LaRosa, J., Pedersen, T. (2006). Abstract
3357: Superiority of ApoB/ApoA1 Ratio for
Predicting Cardiovascular Risk in Pooled
Analyses of the Incremental Decrease in
Endpoints through Aggressive Lipid-Lowering
(IDEAL) and Treating to New Targets (TNT)
Trials. Circulation, 114, II_713-II_714.
Deedwania, P., Barter, P., Carmena, R., Fruchart,
J., Haffner, S., Shepherd, J., Treating to New
Targets, (. (2006). Aggressive lipid lowering
with atorvastatin reduces increased risk of
cardiovascular events in patients with metabolic
syndrome and coronary heart disease. European
Heart Journal, 27(Suppl 1), 931-932.
Barter, P., Ballantyne, C., Carmena, R., Castro
Cabezas, M., Chapman, M., Couture, P., De
Graaf, J., Durrington, P., Faergeman, O.,
Frohlich, J., et al (2006). Apo B versus
cholesterol in estimating cardiovascular risk and
in guiding therapy: report of the
thirty-person/ten-country panel. Journal of
Internal Medicine, 259(3), 247-258. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16476102">[More Information]</a>
Barter, P., Rye, K. (2006). Are we lowering LDL
cholesterol sufficiently? Nature Clinical Practice
Cardiovascular Medicine, 3(6), 290-291. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16728988">[More Information]</a>
Barter, P., Rye, K. (2006). Cardioprotective
Properties of Fibrates: Which Fibrate, Which
Patients, What Mechanism? Circulation,
113(12), 1553-1555.
Teo, K., Nicholls, S., Kee, P., Rye, K., Barter, P.
(2006). Combination high-density lipoprotein
infusion and atorvastatin significantly reduces
experimental atherosclerosis compared to either
therapy alone: serial analysis with
Publications for Philip Barter
high-resolution MRI. European Heart Journal,
27(Suppl 1), 973-974.
anti-inflammatory properties of HDL in vivo.
Atherosclerosis Supplements, 7, 71.
Nicholls, S., Lundman, P., Harmer, J., Cutri, B.,
Griffiths, K., Rye, K., Barter, P., Celermajer, D.
(2006). Consumption of saturated fat impairs the
anti-inflammatory properties of high-density
lipoproteins and endothelial function. Journal of
the American College of Cardiology, 48(4),
715-720. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16904539">[More Information]</a>
Hime, N., Drew, K., Wee, K., Barter, P., Rye, K.
(2006). Formation of high density lipoproteins
containing both apolipoprotein A-I and A-II in
the rabbit. Journal of Lipid Research, 47(1),
115-122. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16222033">[More Information]</a>
Keech, A., Simes, R., Barter, P., Best, J., Scott,
R., Taskinen, M. (2006). Correction to the
FIELD study report. The Lancet, 368(9545),
1415. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17055933">[More Information]</a>
Barrett, P., Barter, P. (2006). Effect of inhibiting
cholesteryl ester transfer protein on the kinetics
of HDL cholesteryl ester transport in plasma: In
vivo studies in rabbits. Atherosclerosis
Supplements, 7, 322.
Waters, D., Barter, P., Kastelein, J., Shah, S.,
Shepherd, J., Wenger, N., LaRosa, J., Treating to
New Targets, (. (2006). Effect of intensive
cholesterol lowering with atorvastatin in patients
with previous coronary bypass surgery: a
Treating to New Targets (TNT) substudy.
European Heart Journal, 27(Suppl 1), 943.
Shepherd, J., Barter, P., Carmena, R.,
Deedwania, P., Fruchart, J., Haffner, S., Hsia, J.,
Breazna, A., LaRosa, J., Grundy, S., et al (2006).
Effect of lowering LDL cholesterol substantially
below currently recommended levels in patients
with coronary heart disease and diabetes - The
treating to new targets (TNT) study. Diabetes
Care, 29(6), 1220-1226.
Waters, D., LaRosa, J., Barter, P., Fruchart, J.,
Gotto Jnr, A., Carter, R., Breazna, A., Kastelein,
J., Grundy, S. (2006). Effects of High-Dose
Atorvastatin on Cerebrovascular Events in
Patients With Stable Coronary Disease in the
TNT (Treating to New Targets) Study. Journal
of the American College of Cardiology, 48(9),
1793-1799. <a
href="http://dx.doi.org/10.1016/j.jacc.2006.07.04
1">[More Information]</a>
Nobecourt, E., Puranik, R., Bao, B., Davies, M.,
Barter, P., Rye, K. (2006). Evidence that
glycation of apolipoprotein. XIV International
Symposium on Atherosclerosis, Ireland: Elsevier
Ireland Ltd.
Nobecourt, E., Puranik, R., Bao, B., Davies, M.,
Barter, P., Rye, K. (2006). Evidence that
glycation of apolipoprotein A-I inhibits the
Barter, P. (2006). From metabolic syndrome to
cardiometabolic risk: The common ground.
Atherosclerosis Supplements, 7, 341.
Rye, K., Barter, P., Bao, B. (2006). HDL and the
inhibition of inflammation in vivo.
Atherosclerosis Supplements, 7, 152.
Heather, A., Barter, P. (2006). HDL exerts novel
anti-inflammatory effects on endothelial cells via
the suppression of NFkB. Atherosclerosis
Supplements, 7, 232.
Tso, C., Martinic, G., Fan, W., Rogers, C., Rye,
K., Barter, P. (2006). High-density lipoproteins
enhance progenitor-mediated endothelium repair
in mice. Arteriosclerosis, Thrombosis, and
Vascular Biology, 26(5), 1144-1149. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16528007">[More Information]</a>
Barter, P., Rye, K. (2006). Homocysteine and
Cardiovascular Disease: Is HDL the Link?
Circulation Research, 99(6), 565-566.
Barter, P. (2006). Managing diabetic
dyslipidaemia - beyond LDL-C: HDL-C and
triglycerides. Atherosclerosis Supplements, 7(4),
17-21. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16828346">[More Information]</a>
Barter, P. (2006). Managing diabetic
dyslipidaemia-beyond LDL-C:HDL-C and
triglycerides. Atherosclerosis Supplements, 7(4),
17-21. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16828346">[More Information]</a>
Barter, P., Gotto Jnr, A., LaRosa, J., Grundy, S.,
Kastelein, J., Bittner, V., Fruchart, J., Treating to
New Targets, (. (2006). On-treatment Levels of
HDL-C and the Ratio of LDL-C/HDL-C as
Predictors of Cardiovascular Events in the
Treating to New Targets (TNT) Study. Journal
of the American College of Cardiology, 47(4
Suppl A), 298A.
Barter, P. (2006). Options for therapeutic
intervention: how effective are the different
agents? European Heart Journal Supplements,
8(Suppl F), F47-F53. <a
Publications for Philip Barter
href="http://dx.doi.org/10.1093/eurheartj/sul041"
>[More Information]</a>
Deedwania, P., Barter, P., Carmena, R., Fruchart,
J., Grundy, S., Haffner, S., Kastelein, J., LaRosa,
J., Schachner, H., Shepherd, J., et al (2006).
Reduction of low-density lipoprotein cholesterol
in patients with coronary heart disease and
metabolic syndrome: analysis of the Treating to
New Targets study. The Lancet, 368(9539),
919-928. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16962881">[More Information]</a>
Rye, K., Bright, R., Psaltis, M., Barter, P. (2006).
Regulation of reconstituted high density
lipoprotein structure and remodeling by
apolipoprotein E. Journal of Lipid Research,
47(5), 1025-1036. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16452453">[More Information]</a>
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16629850">[More Information]</a>
Barter, P., Kastelein, J. (2006). Translating
today's science into clinical practice.
Atherosclerosis Supplements, 7(1 Spec. Iss.), 1-2.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16503207">[More Information]</a>
2005
Puranik, R., Barter, P. (2005). A single infusion
of lipid free Apo A1 can rescue vascular
inflammation, in vivo. Circulation, 112, U320.
Barter, P. (2005). Antiatherogenic Properties of
Fibrates. Arteriosclerosis, Thrombosis, and
Vascular Biology, 25(6), 1095-1096. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15923541">[More Information]</a>
Barter, P., Rye, K. (2006). Relationship between
the concentration and antiatherogenic activity of
high-density lipoproteins. Current Opinion in
Lipidology, 17(4), 399-403. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16832163">[More Information]</a>
Barter, P. (2005). Cardioprotective Effects of
High-Density Lipoproteins: The Evidence
Strengthens. Arteriosclerosis, Thrombosis, and
Vascular Biology, 25(7), 1305-1306. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15980266">[More Information]</a>
Barter, P. (2006). Role of HDL-C and TG
metabolism in abdominal obesity.
Atherosclerosis Supplements, 7, 40.
Stender, S., Schuster, H., Barter, P., Watkins, C.,
Kallend, D. (2005). Comparison of rosuvastatin
with atorvastatin, simvastatin and pravastatin in
achieving cholesterol goals and improving
plasma lipids in hypercholesterolaemic patients
with or without the metabolic syndrome in the
MERCURY I trial. Diabetes, Obesity and
Metabolism, 7(4), 430-438. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15955130">[More Information]</a>
Barter, P., Kastelein, J. (2006). Targeting
cholesteryl ester transfer protein for the
prevention and management of cardiovascular
disease. Journal of the American College of
Cardiology, 47(3), 492-499. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16458126">[More Information]</a>
Barter, P., Rye, K. (2006). The Argument
Against the Appropriateness of Over-the-Counter
Statins. Circulation, 114(12), 1315-1320. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16982953">[More Information]</a>
Keech, A., Simes, R., Barter, P., Best, J., Scott,
R., Taskinen, M. (2006). The FIELD study Reply. The Lancet, 367(9517), 1142-1143.
Rye, K., Nobecourt, E., Puranik, R., Bao, B.,
Barter, P. (2006). The impact of diabetes on the
anti-inflammatory properties of high density
lipoproteins in vivo. European Heart Journal,
27(Suppl 1), 520.
Barter, P., Rye, K. (2006). The rationale for
using apoA-I as a clinical marker of
cardiovascular risk. Journal of Internal
Medicine, 259(5), 447-454. <a
Nicholls, S., Barter, P. (2005). Consumption of
saturated fat impairs endothelial function and the
anti-inflammatory properties of high density
lipoproteins. Circulation, 112, U435-U436.
Nicholls, S., Celermajer, D., Rye, K., Barter, P.,
Griffiths, K., Cutri, B., Harmer, J., Lundman, P.
(2005). Consumption of saturated fat impairs
endothelial function and the antiinflammatory
properties of high-density lipoproteins.
Circulation, 112(17), U43.
Kee, P., Caiazza, D., Rye, K., Barrett, P.,
Morehouse, L., Barter, P. (2005). Effect of
Inhibiting Cholesteryl Ester Transfer Protein on
the Kinetics of High-Density Lipoprotein
Cholesteryl Ester Transport in Plasma: In Vivo
Studies in Rabbits. Arteriosclerosis, Thrombosis,
and Vascular Biology, 26(4), 884-890. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
Publications for Philip Barter
&list_uids=16373610">[More Information]</a>
Waters, D., Barter, P. (2005). Effects of intensive
lipid lowering with atorvastatin on
cerebrovascular events in patients with stable
coronary disease: A treating to new targets
(TNT) substudy. Circulation, 112, U475.
Keech, A., Simes, R., Barter, P., Best, J., Scott,
R., Taskinen, M., Forder, P., Pillai, A., Davis, T.,
Glasziou, P., Sullivan, D., MacMahon, S., et al
(2005). Effects of long-term fenofibrate therapy
on cardiovascular events in 9795 people with
type 2 diabetes mellitus (the FIELD study):
randomised controlled trial. The Lancet,
366(9500), 1849. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16310551">[More Information]</a>
Scott, R., Best, J., Forder, P., Taskinen, M.,
Simes, R., Barter, P., Keech, A. (2005).
Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study: baseline characteristics
and short-term effects of fenofibrate
(ISRCTN64783481). Cardiovascular
Diabetology, 4(13), 1-9. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16111499">[More Information]</a>
Nicholls, S., Rye, K., Barter, P. (2005).
High-density lipoproteins as therapeutic targets.
Current Opinion in Lipidology, 16(3), 345-349.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15891397">[More Information]</a>
Nicholls, S., Cutri, B., Worthley, S., Kee, P.,
Rye, K., Bao, B., Barter, P. (2005). Impact of
short-term administration of high-density
lipoproteins and atorvastatin on atherosclerosis
in rabbits. Arteriosclerosis, Thrombosis, and
Vascular Biology, 25(11), 2416-2421. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16141405">[More Information]</a>
Deedwania, P., Barter, P. (2005). Intensive lipid
lowering with atorvastatin in patients with
metabolic syndrome and stable coronary disease.
Circulation, 112, U726.
LaRosa, J., Grundy, S., Waters, D., Shear, C.,
Barter, P., Fruchart, J., Gotto Jnr, A., Greten, H.,
Kastelein, J., Shepherd, J., et al (2005). Intensive
lipid lowering with atorvastatin in patients with
stable coronary disease. New England Journal of
Medicine, 352(14), 1425-1435. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15755765">[More Information]</a>
Barter, P. (2005). Measuring effective reductions
in cholesterol using rosuvastatin therapy
(Mercury I): Safety analysis from an open-label
extension. Atherosclerosis Supplements, 6, 101.
Yu, Y., Wyszynski, D., Waterworth, D., Wilton,
S., Barter, P., Kesaniemi, Y., Mahley, R.,
McPherson, R., Waeber, G., Bersot, T., et al
(2005). Multiple QTLs influencing triglyceride
and HDL and total cholesterol levels identified in
families with atherogenic dyslipidemia. Journal
of Lipid Research, 46(10), 2202-2213. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16061952">[More Information]</a>
Tonkin, A., Barter, P., Best, J., Boyden, A.,
Furler, J., Hossack, K., Sullivan, D., Thompson,
P., Vale, M., Cooper, C., et al (2005). National
Heart Foundation of Australia and the Cardiac
Society of Australia and New Zealand: position
statement on lipid management--2005. Heart,
Lung and Circulation, 14(4), 275. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16361000">[More Information]</a>
Nicholls, S., Dusting, G., Cutri, B., Bao, B.,
Drummond, G., Rye, K., Barter, P. (2005).
Reconstituted high-density lipoproteins inhibit
the acute pro-oxidant and proinflammatory
vascular changes induced by a periarterial collar
in normocholesterolemic rabbits. Circulation,
111(12), 1543-1550. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15781735">[More Information]</a>
Wyszynski, D., Waterworth, D., Barter, P.,
Cohen, J., Kesaniemi, Y., Mahley, R.,
McPherson, R., Waeber, G., Bersot, T., Sharma,
S., et al (2005). Relation Between Atherogenic
Dyslipidemia and the Adult Treatment
Program-III Definition of Metabolic Syndrome
(Genetic Epidemiology of Metabolic Syndrome
Project). The American Journal of Cardiology,
95(2), 194-198. <a
href="http://dx.doi.org/10.1016/j.amjcard.2004.0
8.091">[More Information]</a>
Barter, P. (2005). Role of nicotinic acid in
raising high-density lipoprotein cholesterol
(HDL-C) to reduce cardiovascular risk: an
Asian/Pacific consensus. British Journal of
Diabetes and Vascular Disease, 5, 1-16.
Barter, P. (2005). The inflammation: Lipoprotein
cycle. Atherosclerosis Supplements, 6(2), 15-20.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15823492">[More Information]</a>
Settasatian, N., Barter, P., Rye, K. (2005). The
Influence of Apolipoprotein E Isoforms on High
Density Lipoprotein Remodelling by
Publications for Philip Barter
Phospholipid Transfer Protein. Arteriosclerosis,
Thrombosis, and Vascular Biology, 25(5), E-90.
Type 2 diabetes patients in the MERCURY I
study. Diabetologia, 47, A409.
Barter, P. (2005). The realities of dyslipidaemia
in metabolic syndrome and diabetes. British
Journal of Diabetes and Vascular Disease,
5(Suppl 1), S7-S11.
Schuster, H., Barter, P., Stender, S., Cheung, R.,
Bonnet, J., Morrell, J., Watkins, C., Kallend, D.,
Raza, A. (2004). Effects Of Switching Statins On
Achievement Of Lipid Goals: Measuring
Effective Reductions In Cholesterol Using
Rosuvastatin Therapy (Mercury I) Study.
American Heart Journal, 147(4), 705-713. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15077101">[More Information]</a>
Barter, P. (2005). The role of HDL-cholesterol in
preventing
atherosclerotic disease. European Heart Journal
Supplements, 7(F), F4-F8.
Settasatian, C., van der Meer, A., Rader, D.,
Barter, P., Rye, K. (2005). The Role of the Beta5
Loop of Endothelial Lipase in the Hydrolysis of
Reconstituted High-Density Lipoprotein
Phospholipids. Arteriosclerosis, Thrombosis, and
Vascular Biology, 25(5), E-76.
Barter, P. (2005). Why should we target HDL to
further improve CHD prevention?
Atherosclerosis Supplements, 6, 177-178.
2004
Barter, P., Nicholls, S., Rye, K.,
Anantharamaiah, G., Navab, M., Fogelman, A.
(2004). Antiinflammatory Properties Of HDL.
Circulation Research, 95(8), 764-772. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15486323">[More Information]</a>
Nicholls, S., Barter, P., Bao, B. (2004).
Apolipoprotein composition influences the
ability of reconstituted high density lipoproteins
to promote a stable plaque phenotype.
Circulation, 110, 37.
Hime, N., Drew, K., Hahn, C., Barter, P., Rye,
K. (2004). Apolipoprotein E Enhances Hepatic
Lipase-Mediated Hydrolysis of Reconstituted
High-Density Lipoprotein Phospholipid and
Triacylglycerol in an Isoform-Dependent
Manner. Biochemistry, 43(38), 12306-12314.
Hime, N., Drew, K., Hahn, C., Barter, P., Rye,
K. (2004). Apolipoprotein E Enhances Hepatic
Lipase-Mediated Hydrolysis Of Reconstituted
High-Density Lipoprotein Phospholipid And
Triacylglycerol In An Isoform-Dependent
Manner. Biochemistry, 43(38), 12306-12314.
Colquhoun, D., Keech, A., Hunt, D., Marschner,
I., Simes, R., Glasziou, P., White, H., Barter, P.,
Tonkin, A. (2004). Effects Of Pravastatin On
Coronary Events In 2073 Patients With Low
Levels Of Both Low-Density Lipoprotein
Cholesterol And High-Density Lipoprotein
Cholesterol: Results From The Lipid Study.
European Heart Journal, 25(9), 771-777. <a
href="http://dx.doi.org/10.1016/j.ehj.2004.03.01
3">[More Information]</a>
Schuster, H., Barter, P. (2004). Effects of
rosuvastatin and atorvastatin on plasma lipids in
Barter, P. (2004). Effects of switching statins on
non-HDL-C in hypercholesterolaemic patients
and achievement of ATP III combined LDL-C
and non-HDL-C goals in patients with elevated
triglycerides: Mercury I trial results.
Atherosclerosis Supplements, 5, 106.
Rye, K., Barter, P. (2004). Formation And
Metabolism Of Prebeta-Migrating, Lipid-Poor
Apolipoprotein A-I. Arteriosclerosis,
Thrombosis, and Vascular Biology, 24(3),
421-428. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=14592845">[More Information]</a>
Shepherd, J., Hunninghake, D., Barter, P.,
McKenney, J., Hutchinson, H. (2004).
Guidelines for lowering lipids to reduce coronary
artery disease risk: a comparison of rosuvastatin
with atorvastatin, pravastatin, and simvastatin for
achieving lipid-lowering goals. 2003.
Atherosclerosis Supplements, 5(3), 115-123. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15531284">[More Information]</a>
Barter, P. (2004). HDL: A Recipe For Longevity.
Atherosclerosis Supplements, 5(2), 25-31. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15121032">[More Information]</a>
Wadham, C., Albanese, N., Roberts, J., Wang,
L., Bagley, C., Gamble, J., Rye, K., Barter, P.,
Vadas, M., Xia, P. (2004). High-Density
Lipoproteins Neutralize C-Reactive Protein
Proinflammatory Activity. Circulation, 109(17),
2116-2122. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15078800">[More Information]</a>
Hime, N., Drew, K., Barter, P., Rye, K. (2004).
In Vivo Formation of High-Density Lipoproteins
Containing Both Apolipoprotein A-I and
Apolipoprotein A-II in the Rabbit.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 24(5), E-104.
Barter, P. (2004). Is High-Density Lipoprotein
Publications for Philip Barter
The Protector Of The Cardiovascular System?
European Heart Journal Supplements,
6(Supplement A), A19-A22.
Barter, P. (2004). Metabolic Abnormalities:
High-Density Lipoproteins. Endocrinology and
Metabolism Clinics of North America, 33(2),
393-403. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15158525">[More Information]</a>
Tso, C., Barter, P. (2004). Recruitment of
endothelial progenitor cells into
lipopolysaccharide-stimulated mouse aortic
endothelium. Circulation, 110, 151.
Keech, A., Best, J., Scott, R., Barter, P., Simes,
R., Forder, P., Taskinen, M., FIELD study
investigators, F. (2004). Significant lipid changes
in a large-scale trial of fenofibrate to prevent
cardiovascular disease in type 2 diabetes.
Journal of the American College of Cardiology,
43(5), A462-A462.
Barter, P., Best, J., Colman, P., D'Emden, M.,
Davis, T., Drury, P., Ehnholm, C., Glasziou, P.,
Hunt, D., Keech, A., Forder, P., Simes, R., et al
(2004). The need for a large-scale trial of fibrate
therapy in diabetes: the rationale and design of
the Fenofibrate Intervention and Event Lowering
in Diabetes (FIELD) study. Cardiovascular
Diabetology, 3(December), 9 - 1-9 - 11.
2003
Rye, K., Wee, K., Curtiss, L., Bonnet, D., Barter,
P. (2003). Apolipoprotein-A-II inhibits high
density lipoprotein remodeling and lipid-poor
apolipoprotein A-I formation. Journal of
Biological Chemistry, 278(25), 22530-22536.
Barter, P., Brewer, H., Chapman, M.,
Hennekens, C., Rader, D., Tall, A. (2003).
Cholesteryl ester transfer protein. A novel target
for raising HDL and inhibiting atherosclerosis.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 23(2), 160-167.
Duong, M., Psaltis, M., Rader, D., Marchadier,
D., Barter, P., Rye, K. (2003). Evidence that
hepatic lipase and endothelial lipase have
different substrate specificities for high-density
lipoprotein phospholipids. Biochemistry, 42(46),
13778-13785. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=14622025">[More Information]</a>
2002
Rye, K., Duong, M., Psaltis, M., Curtiss, L.,
Bonnet, D., Stocker, R., Barter, P. (2002).
Evidence that phospholipids play a key role in
pre-β apoA-I formation and high density
lipoprotein remodeling. Biochemistry, 41(41),
12538-12545.